Institute of Hematology & Blood Diseases Hospital, China: Hematologic Neoplasms trials

The registry lists 10 Hematologic Neoplasms studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 3No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07678307Phase 1/2
• The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary InfiltratingNot yet recruitingNCT07456189Not applicable
• The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood TransplantationNot yet recruitingNCT07441967Phase 2
• Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and SafetyRecruitingNCT07185503
• A Study of the Effect of Laughter Therapy on the Mental Health and Quality of Survival of Hematopoietic Stem Cell Transplant PatientsNot yet recruitingNCT06792630Not applicable
• National Longitudinal Cohort of Hematological Diseases (NICHE) - CARTRecruitingNCT06607289
• An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)RecruitingNCT06490549
• A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological MalignanciesAvailableNCT04008524
• Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From ChinaCompletedNCT06900114
• CD7 CAR-T for Patients With r/r CD7+ Hematologic MalignanciesCompletedNCT05454241Phase 2